Details for New Drug Application (NDA): 020450

✉ Email this page to a colleague

NDA 020450 describes CEREBYX, which is a drug marketed by Parke Davis and is included in one NDA. It is available from one supplier. Additional details are available on the CEREBYX profile page.

The generic ingredient in CEREBYX is fosphenytoin sodium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fosphenytoin sodium profile page.

Summary for 020450

Tradename:	CEREBYX
Applicant:	Parke Davis
Ingredient:	fosphenytoin sodium
Patents:	0

Pharmacology for NDA: 020450

Mechanism of Action	Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inducers Cytochrome P450 3A Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Suppliers and Packaging for NDA: 020450

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CEREBYX	fosphenytoin sodium	INJECTABLE;INJECTION	020450	NDA	Pfizer Laboratories Div Pfizer Inc	0069-5471	0069-5471-02	25 VIAL, SINGLE-DOSE in 1 CARTON (0069-5471-02) / 2 mL in 1 VIAL, SINGLE-DOSE (0069-5471-01)
CEREBYX	fosphenytoin sodium	INJECTABLE;INJECTION	020450	NDA	Pfizer Laboratories Div Pfizer Inc	0069-5474	0069-5474-02	10 VIAL, SINGLE-DOSE in 1 PACKAGE (0069-5474-02) / 10 mL in 1 VIAL, SINGLE-DOSE (0069-5474-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	EQ 50MG PHENYTOIN NA/ML
Approval Date:	Aug 5, 1996	TE:	AP	RLD:	Yes

Expired US Patents for NDA 020450

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Parke Davis	CEREBYX	fosphenytoin sodium	INJECTABLE;INJECTION	020450-001	Aug 5, 1996	4,260,769	⤷ Subscribe
Parke Davis	CEREBYX	fosphenytoin sodium	INJECTABLE;INJECTION	020450-001	Aug 5, 1996	4,925,860	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.